Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anant Narayan Bhatt has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Anti-cancer drug-mediated increase in mitochondrial mass limits the application of metabolic viability-based MTT assay in cytotoxicity screening

    by Abhishek Kumar, Yogesh Rai, Anant Narayan Bhatt

    The high-throughput metabolic viability-based colorimetric MTT test is commonly employed to screen the cytotoxicity of different chemotherapeutic drugs. The assay assumes a cell density-dependent linear correlation with the MTT spectral absorbance. Therefore, the present study aimed to compare the cytotoxicity assessment between the MTT assay and gold standard cell number enumeration. The cytotoxicity was induced by Cisplatin, Etoposide, and Doxorubicin in human lung epithelial adenocarcinoma cells (A549) and cervix carcinoma (HeLa) cell lines. The mitochondrial mass was estimated, and immunoblotting of succinate dehydrogenase (SDH-A) was performed following drug treatment in both cell lines. Student’s t-test paired analysis was employed to calculate the significance of the results, where the value p < 0.05 was considered statistically significant. The drug-induced cytotoxic response estimated by MTT absorbance did not show any significant difference with respect to control, and no correlation was observed with the enumerated cell number in both A549 and HeLa cells. Interestingly, per-cell metabolic viability was found to be increased by 1.18 to 3.26-fold (p < 0.05) following drug treatment. Further, mechanistic investigation revealed a drug concentration-dependent significant increase in mitochondrial mass (1.21 to 4.2-fold) and upregulation of SDH protein (50–70%) as well as enzymatic activity with respect to control in both A549 and Hela cells. The limitation of the MTT assay for drug-induced cytotoxicity assessment is due to increased mitochondrial mass and SDH upregulation in surviving cells, leading to enhanced formazan formation. This leads to a lack of correlation between cell number and MTT spectral absorbance, suggesting that the MTT assay may provide an erroneous conclusion for cytotoxicity assessment.


  • Granular Hemostatic Composite of Alginate, Calcium, and Zinc for Rapid and Effective Management of Post-Traumatic Hemorrhage

    by Abhishek Kumar, Dhananjay K. Sah, Yogesh Rai, Amit K. Yadav, Pratima R. Solanki, Mohd Saquib Ansari, Anant N. Bhatt

    Post-traumatic hemorrhage, which can result from accidents or battlefield injuries, is a significant global concern due to the high prehospital mortality rate. Substantial efforts have been made to develop hemostatic agents that can effectively reduce hemorrhage in the immediate aftermath of a traumatic event. The present study investigated the potential efficacy of Ca2+ and Zn2+ supplemented sodium alginate-based dry hemostatic particles (SA-CZ DHP) to manage excessive blood loss or post-traumatic hemorrhage. SA-CZ DHP were developed, followed by their physical and biochemical characterization, cytocompatibility and hemocompatibility testing, and critical evaluation of the hemostatic potential in vitro and in vivo. The safe SA-CZ DHP showed high absorption and accelerated blood clotting kinetics with reduced coagulation time (≈70%, p < 0.0001) in whole human blood, observed with insignificant hemolysis and uninterrupted RBC morphology. SA-CZ DHP significantly reduced the mean blood loss (≈90% in SD rats tail incision), and bleeding time (≈60% in BALB/c mice tail incision) was at par with commercially available Celox hemostatic granules. In conclusion, the biocompatible SA-CZ DHP exhibited rapid and effective management of excessive blood loss. It is also pertinent to note that the developed formulation could be a cost-effective alternative to its commercial counterparts.


  • Open Access

    Anti-cancer drug-induced mitochondrial alteration becomes a limitation of metabolic viability-based MTT assay in analyzing growth inhibition

    by Abhishek Kumar, Yogesh Rai, Anant Narayan Bhatt

    Background High throughput metabolic viability-based colorimetric MTT assay is widely used for cytotoxicity screening of various chemical compounds, anti-neoplastic drugs, and other chemotherapeutic agents. The yellow MTT tetrazolium salt reduces to purple formazan crystals, predominantly by mitochondrial dehydrogenases. The assay assumes all cells have a similar number of mitochondria with equivalent enzymatic activity, resulting in a linear relationship between colorimetric absorbance and cell number. Method Our present study involved the Cisplatin, Etoposide, and Doxorubicin-induced cytotoxicity evaluation using MTT and cell number enumeration in two widely used cancer cell lines, namely human lung epithelial adenocarcinoma cells (A549) and cervix carcinoma (HeLa). Further, Mitochondrial mass was examined to comment on the treatment-induced change in metabolic viability-based MTT assay. Results Drug-induced cell death determined by enumeration of the cell number did not correlate with growth inhibition observed by the MTT assay. Increased protein levels of majorly MTT converting enzyme SDH in both the cell lines following drug treatment were observed. The mitochondrial protein content of the cells was also found to be elevated in response to drug-induced cytotoxic stress. Conclusion In line with our earlier observation about the limitation of MTT assay in estimating radiation-induced cytotoxicity, it was found that certain anti-neoplastic drugs also modulate mitochondrial biogenesis and SDH expression level and enzymatic activity. Therefore, caution should be taken in applying the MTT assay to analyze drug-induced growth inhibition. General significance: Our findings reveal the MTT assay's limitations, which should be considered when determining anti-cancer and chemotherapeutic drugs' pre-clinical cytotoxicity and IC-50.


  • Open Access

    Mitochondrial uncoupler DNP induces coexistence of dual-state hyper-energy metabolism leading to tumor growth advantage in human glioma xenografts

    by Yogesh Rai, Saurabh Singh, Sanjay Pandey, Dhananjay Sah, Raj Kumar Sah, B. G. Roy, Bilikere S. Dwarakanath, Anant Narayan Bhatt

    Introduction: Cancer bioenergetics is an essential hallmark of neoplastic transformation. Warburg postulated that mitochondrial OXPHOS is impaired in cancer cells, leading to aerobic glycolysis as the primary metabolic pathway. However, mitochondrial function is altered but not entirely compromised in most malignancies, and that mitochondrial uncoupling is known to increase the carcinogenic potential and modifies treatment response by altering metabolic reprogramming. Our earlier study showed that transient DNP exposure increases glycolysis in human glioma cells (BMG-1). The current study investigated the persistent effect of DNP on the energy metabolism of BMG-1 cells and its influence on tumor progression in glioma xenografts.Methods: BMG-1 cells were treated with 2,4-dinitrophenol (DNP) in-vitro, to establish the OXPHOS-modified (OPM-BMG) cells. Further cellular metabolic characterization was carried out in both in-vitro cellular model and in-vivo tumor xenografts to dissect the role of metabolic adaptation in these cells and compared them with their parental phenotype. Results and Discussion: Chronic exposure to DNP in BMG-1 cells resulted in dual-state hyper-energy metabolism with elevated glycolysis++ and OXPHOS++ compared to parental BMG-1 cells with low glycolysis+ and OXPHOS+. Tumor xenograft of OPM-BMG cells showed relatively increased tumor-forming potential and accelerated tumor growth in nude mice. Moreover, compared to BMG-1, OPM-BMG tumor-derived cells also showed enhanced migration and invasion potential. Although mitochondrial uncouplers are proposed as a valuable anti-cancer strategy; however, our findings reveal that prolonged exposure to uncouplers provides tumor growth advantage over the existing glioma phenotype that may lead to poor clinical outcomes.


  • Top Cited Papers

    A calcium and zinc composite alginate hydrogel for pre-hospital hemostasis and wound care

    by Abhishek Kumar, Dhananjay Kumar Sah, Kushagra Khanna, Yogesh Rai, Amit Kumar Yadav, Mohd Saquib Ansari, Anant Narayan Bhatt


  • Open Access

    2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

    by Anant Narayan Bhatt, Srinivas Shenoy, Sagar Munjal, Vijayakumar Chinnadurai, Apurva Agarwal, A. Vinoth Kumar, A. Shanavas, Ratnesh Kanwar, Sudhir Chandna

    Background: At present, no single efficacious therapeutic exists for acute COVID-19 management and a multimodal approach may be necessary. 2-deoxy-d-glucose (2-DG) is a metabolic inhibitor that has been shown to limit multiplication of SARS-CoV-2 in-vitro. We evaluated the efficacy and safety of 2-DG as adjunct to standard care in the treatment of moderate to severe COVID-19 patients. Methods: We conducted a randomized, open-label, phase II, clinical study to evaluate the efficacy, safety, and tolerability of 2-DG administered as adjunct to standard of care (SOC). A total of 110 patients between the ages of 18 and 65 years with moderate to severe COVID-19 were included. Patients were randomized to receive 63, 90, or 126 mg/kg/day 2-DG in addition to SOC or SOC only. Times to maintaining SpO2 ≥ 94% on room air, discharge, clinical recovery, vital signs normalisation, improvement by 1 and 2 points on WHO clinical progression scale, negative conversion on RT-PCR, requirement for intensive care, and mortality were analyzed to assess the efficacy. Results: Patients treated with 90 mg/kg/day 2-DG plus SOC showed better outcomes. Time to maintaining SpO2 ≥ 94% was significantly shorter in the 2-DG 90 mg compared to SOC (median 2.5 days vs. 5 days, Hazard ratio [95% confidence interval] = 2.3 [1.14, 4.64], p = 0.0201). Times to discharge from isolation ward, to clinical recovery, and to vital signs normalization were significantly shorter for the 2-DG 90 mg group. All three doses of 2-DG were well tolerated. Thirty-three (30.3%) patients reported 65 adverse events and were mostly (86%) mild. Conclusions: 2-DG 90 mg/kg/day as adjunct to SOC showed clinical benefit over SOC alone in the treatment of moderate to severe COVID-19. The promising trends observed in current phase II study is encouraging for confirmatory evaluation of the efficacy and safety of 2-DG in a larger phase III trial. Trial registration: CTRI, CTRI/2020/06/025664. Registered 5th June 2020, http://ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=44369&EncHid=&modid=&compid=%27,%2744369det%27.


  • Open Access

    Gamma-Linolenic Acid (GLA) Protects against Ionizing Radiation-Induced Damage: An In Vitro and In Vivo Study

    by Poorani Rengachar, Anant Narayan Bhatt, Sailaja Polavarapu, Senthil Veeramani, Anand Krishnan, Monika Sadananda, Undurti N. Das

    Radiation is pro-inflammatory in nature in view of its ability to induce the generation of reactive oxygen species (ROS), cytokines, chemokines, and growth factors with associated inflammatory cells. Cells are efficient in repairing radiation-induced DNA damage; however, exactly how this happens is not clear. In the present study, GLA reduced DNA damage (as evidenced by micronuclei formation) and enhanced metabolic viability, which led to an increase in the number of surviving RAW 264.7 cells in vitro by reducing ROS generation, and restoring the activities of desaturases, COX-1, COX-2, and 5-LOX enzymes, TNF-α/TGF-β, NF-kB/IkB, and Bcl-2/Bax ratios, and iNOS, AIM-2, and caspases 1 and 3, to near normal. These in vitro beneficial actions were confirmed by in vivo studies, which revealed that the survival of female C57BL/6J mice exposed to lethal radiation (survival~20%) is significantly enhanced (to ~80%) by GLA treatment by restoring altered levels of duodenal HMGB1, IL-6, TNF-α, and IL-10 concentrations, as well as the expression of NF-kB, IkB, Bcl-2, Bax, delta-6-desaturase, COX-2, and 5-LOX genes, and pro- and anti-oxidant enzymes (SOD, catalase, glutathione), to near normal. These in vitro and in vivo studies suggest that GLA protects cells/tissues from lethal doses of radiation by producing appropriate changes in inflammation and its resolution in a timely fashion.


  • Amifostine analog, DRDE-30, alleviates radiation induced lung damage by attenuating inflammation and fibrosis

    by Aastha Arora, Vikas Bhuria, Saurabh Singh, Uma Pathak, Sweta Mathur, Puja P. Hazari, Bal G. Roy, Rajat Sandhir, Ravi Soni, Bilikere S. Dwarakanath, et al.


  • Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions

    by Anant Narayan Bhatt, Abhishek Kumar, Yogesh Rai, Neeraj Kumari, Dhiviya Vedagiri, Krishnan H. Harshan, Vijayakumar Chinnadurai, Sudhir Chandna


  • Metabolic Oxidative Stress in Initiation, Progression, and Therapy of Cancer

    by Soumen Bera, Amit Verma, Anant N. Bhatt, Bilikere S. Dwarakanath